

PERSONAL INFORMATION

Dr. Andrej Janžič

WORK EXPERIENCE

Apr 2021 →

Head of Medicinal Products and Medical Devices Division
Ministry of Health, Republic of Slovenia

- Responsible for development of strategies on national level related to Medicines and Medical Devices, HTA, Pharmacy services, Blood, Tissue and Cells, Health Spa and Healing.
- Leading project teams for the most demanding and key projects.
- Direct assistance to Director-General.
- Preparing the legislative acts and coordination of the adoption of regulations.
- Expert support in the preparation of Slovenia's positions on proposal of legislative acts on EU level or other relevant international subjects.
- Design of key system solutions and ensuring the development of the organization.
- Managing the team and task coordination.

Nov 2018 → Apr 2021

Head of Division for pharmacoeconomics, market monitoring and HTA
Agency for Medicinal Products and Medical Devices of the Republic of Slovenia

- Responsible for the processes of Pricing of medicinal products, Market monitoring, Health technology assessment, and Essential list of medicines.
- Development of guidelines and internal procedures related to HTA, pricing, reimbursement, availability and accessibility of medicines and medical devices.
- Development of the pricing system in Slovenia, including conceptualization of the strategy of integration of the latest scientific findings and modern methods.
- Involvement in the preparation of legislation at national and EU level.
- Participation in EU affairs related to medicines (e.g. representative in the Pharmaceutical Committee at European Commission).
- EUnetHTA JA3 (WP4 – Joint Production; WP5 – Lifecycle Approach to improve Evidence Generation) project leader at JAZMP.
- Lead the team, with focus on open and positive work environment that is inspiring to work and growth, attaining new knowledge and skills.

Sept 2018 → Nov 2018

Secretary, HTA expert
Agency for Medicinal Products and Medical Devices of the Republic of Slovenia

- Development of guidelines and other legislation acts related to HTA, including pricing, reimbursement, availability and accessibility of medicines and medical devices.
- Actively participating in EU networks as expert and representative of Slovenia.
- Performing the evaluation of medicine and medical devices, including efficacy, relative effectiveness and safety, health economics and impact on organization of healthcare.
- Expert scientific advice for health policy development on a broad field of medicines, including regulatory, pharmacy services etc.

Apr 2010 → Avg 2018

Teaching Assistant and Researcher
University of Ljubljana, Faculty of Pharmacy

- *Higher Education* - Lectures, Practice Exercises, Mentorship in the field of social pharmacy, health economics, Evidence based medicine (clinical trials, meta-analysis, network meta-analysis, indirect comparison), marketing, biostatistics, traineeship.
- *Research* – individual research and as part of research groups. Design, conduct, analysis and interpretation of different type of studies, including pharmacoeconomic, pharmacoepidemiologic, observational, clinical and other studies.
- *Professional work* – consultancy, scientific advices, reviews of articles for scientific journals

Okt 2009 – Mar 2010

Regulatory specialist
Lek, member of Sandoz group*Sales and marketing, Country organization for regulatory affairs*

- Preparing the documentation for obtaining marketing authorization, renewal or variations. National translations of specific documents, including Patient Information (PL, SmPC, etc.). Professional communication with official authorities and headquarter. Collaboration with other departments, especially marketing, in preparing the national registration and marketing strategy

EDUCATION AND TRAINING

2011 - 2017	PhD in biomedicine University of Ljubljana, Slovenia	EQF level 8
2003 - 2009	Master of Pharmacy University of Ljubljana, Faculty of Pharmacy, Slovenia	

ADDITIONAL INFORMATION

- Research**
- The economic value of clinical trials and their contributions to the reimbursement of medicines and medical services (Value of Information research)
 - Cost-effectiveness of novel oral anticoagulants
 - Assessment of organization of anticoagulation care and possible improvements
 - Availability of medicines for rare diseases in Europe
 - Dynamics of medicine prices in Slovenia and influential factors
 - Criteria for reimbursement decision-making process
 - Evaluation of access to novel oncological medicines
 - Prescribing patterns of medicines in Slovenia (research on health claims database)
 - Shortages of medicines in Slovenia

- Scientific articles**
- JANŽIČ, Urška, KNEZ, Lea, JANŽIČ, Andrej, ČUFER, Tanja. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia. Expert review of pharmacoeconomics & outcomes research. vol. 19, iss. 6, str. 717-723, ilustr. ISSN 1744-8379.
 - DETIČEK, Andreja, JANŽIČ, Andrej, LOCATELLI, Igor, KOS, Mitja. Decision-making criteria for medicine reimbursement in Slovenia : an expert panel discussion. BMC health services research. Jun. 2018, vol. 18, str. 1-13, tabele. ISSN 1472-6963.
 - JANŽIČ, Andrej, KOS, Mitja. Influence of novel oral anticoagulants on management of anticoagulation care. Acta pharmaceutica. 2017, vol. 67, no. 3, str. 397-406, ilustr. ISSN 1330-0075.
 - JANŽIČ, Andrej, LOCATELLI, Igor, KOS, Mitja. The value of evidence in the decision-making process for reimbursement of pharmacogenetic dosing of warfarin. American journal of cardiovascular drugs. 2017, vol. 17, iss. 5, str. 399-408, ilustr. ISSN 1175-3277.
 - JANŽIČ, Urška, KERN, Izidor, JANŽIČ, Andrej, ČAVKA, Luka, ČUFER, Tanja. PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung. Radiology and oncology. [Print ed.]. 2017, vol. 51, no. 3, str. 357-362, xi, ilustr. ISSN 1318-2099.
 - JANŽIČ, Andrej, KOS, Mitja. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. PharmacoEconomics. 2015, vol. 33, iss. 4, str. 395-408. ISSN 1170-7690.